Anti-SARS-CoV-2 T-cell Responses After mRNA Vaccination in Belatacept-treated Renal Transplant Patients

Transplantation. 2021 Sep 1;105(9):e99. doi: 10.1097/TP.0000000000003812.

Authors

Sebastian Dolff¹, Johannes Korth², Michael Jahn², Andreas Kribben², Oliver Witzke¹, Benjamin Wilde²

Affiliations

¹ Department of Infectious Diseases, West German Centre of Infectious Diseases, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.
² Department of Nephrology, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.

PMID: 33966023
DOI: 10.1097/TP.0000000000003812

No abstract available

Publication types

Research Support, Non-U.S. Gov't
Comment

MeSH terms

Abatacept / therapeutic use
Humans
Immunosuppressive Agents / adverse effects
Kidney Transplantation* / adverse effects
RNA, Messenger
SARS-CoV-2
T-Lymphocytes / immunology
Transplant Recipients
Vaccination
Vaccines*

Substances

Immunosuppressive Agents
RNA, Messenger
Vaccines
Abatacept